
Grünenthal chief executive Eric-Paul Pâques to retire; new CEO named
pharmafile | June 7, 2016 | Appointment | | CEO, Grünenthal Group, appointment
Germany-based Grünenthal Group on Tuesday named Gabriel Baertschi its chief executive officer effective October 1, 2016.
He succeeds Eric-Paul Pâques who will retire at the end of 2016 after 23 years with the family-owned company.
Baertschi will join from AstraZeneca (LSE: AZN) where he currently serves as president for Japan.
Gabriel Baertschi said: “I am honored to have been elected as Grünenthal’s CEO. It is a privilege to be part of an organization that delivers high quality products and innovative solutions to the patients. Grünenthal is an organization led by a purpose: to bring true benefits to patients by being an entrepreneurial specialist. I am deeply committed to building long-term value for patients, clinicians, and our partners together with a very experienced team at Grünenthal.”
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …






